These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 10618605)

  • 1. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Lladó L; Virgili J; Figueras J; Valls C; Dominguez J; Rafecas A; Torras J; Fabregat J; Guardiola J; Jaurrieta E
    Cancer; 2000 Jan; 88(1):50-7. PubMed ID: 10618605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors.
    Mondazzi L; Bottelli R; Brambilla G; Rampoldi A; Rezakovic I; Zavaglia C; Alberti A; Idèo G
    Hepatology; 1994 May; 19(5):1115-23. PubMed ID: 7513677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session].
    El Khaddari S; Gaudin JL; Abidi H; Picaud G; Rode A; Souquet JC
    Gastroenterol Clin Biol; 2002; 26(8-9):728-34. PubMed ID: 12434077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization.
    Kim JH; Yoon HK; Ko GY; Gwon DI; Jang CS; Song HY; Shin JH; Sung KB
    Radiology; 2010 Apr; 255(1):270-7. PubMed ID: 20308463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Single center experience over a 5-year period with sequential transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC)].
    Herber SC; Otto G; Woerns M; Moench C; Kanzler S; Junginger T; Schneider J; Schuchmann M; Kummer I; Manzl N; Düber C; Pitton MB
    Rofo; 2007 Mar; 179(3):289-99. PubMed ID: 17325996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS; Park MH; Jeon GS
    Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Hiraoka A; Horiike N; Yamashita Y; Koizumi Y; Doi H; Yamamoto Y; Ichikawa S; Hasebe A; Yano M; Miyamoto Y; Ninomiya T; Ootani H; Takamura K; Kawasaki H; Otomi Y; Kogame M; Sogabe I; Ishimaru Y; Kashihara K; Miyagawa M; Hirooka M; Hiasa Y; Matsuura B; Michitaka K; Onji M
    Hepatogastroenterology; 2009; 56(89):213-7. PubMed ID: 19453060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization.
    Liu MT; Li SH; Chu TC; Hsieh CY; Wang AY; Chang TH; Pi CP; Huang CC; Lin JP
    Jpn J Clin Oncol; 2004 Sep; 34(9):532-9. PubMed ID: 15466827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
    Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
    [No Abstract]   [Full Text] [Related]  

  • 10. [Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma].
    Jeon SH; Park KS; Kim YH; Shin YS; Kang MK; Jang BK; Chung WJ; Cho KB; Hwang JS
    Korean J Gastroenterol; 2007 Sep; 50(3):176-82. PubMed ID: 17885283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemoembolization of hepatocellular carcinomas: which factors determine therapeutic response and survival?].
    Huppert PE; Lauchart W; Duda SH; Torkler C; Kloska SP; Weinlich M; Benda N; Pereira P; Claussen CD
    Rofo; 2004 Mar; 176(3):375-85. PubMed ID: 15026951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma.
    Cheng JC; Chuang VP; Cheng SH; Huang AT; Lin YM; Cheng TI; Yang PS; You DL; Jian JJ; Tsai SY; Sung JL; Horng CF
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):435-42. PubMed ID: 10802371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT volume measurement for prognostic evaluation of unresectable hepatocellular carcinoma after TACE.
    Zhang JW; Feng XY; Liu HQ; Yao ZW; Yang YM; Liu B; Yu YQ
    World J Gastroenterol; 2010 Apr; 16(16):2038-45. PubMed ID: 20419843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study.
    Biselli M; Andreone P; Gramenzi A; Trevisani F; Cursaro C; Rossi C; Ricca Rosellini S; Cammà C; Lorenzini S; Stefanini GF; Gasbarrini G; Bernardi M
    Clin Gastroenterol Hepatol; 2005 Sep; 3(9):918-25. PubMed ID: 16234031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors.
    Ueno K; Miyazono N; Inoue H; Nishida H; Kanetsuki I; Nakajo M
    Cancer; 2000 Apr; 88(7):1574-81. PubMed ID: 10738215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma.
    O'Suilleabhain CB; Poon RT; Yong JL; Ooi GC; Tso WK; Fan ST
    Br J Surg; 2003 Mar; 90(3):325-31. PubMed ID: 12594668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma invading the main portal vein: treatment with transcatheter arterial chemoembolization and portal vein stenting.
    Zhang XB; Wang JH; Yan ZP; Qian S; Liu R
    Cardiovasc Intervent Radiol; 2009 Jan; 32(1):52-61. PubMed ID: 18931871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.